HENDERSON, NV / ACCESSWIRE / January 28, 2019 / Biotech can be a lucrative sector for investors. Companies in the industry are often working toward well-defined goals such as clinical trial results, which if achieved can lead to significant returns.
An oversold biotech with huge upside potential we really like is Delcath Systems, Inc. (DCTH). Last September, the stock reached highs above $8 and is now sitting around support at $0.26. With promising liver cancer treatments in late-stage development (registration trials), increased revenue this past year, and a new licensing deal with a projected value of up to $45 million, there is a lot for potential investors to be excited about. With not much awareness among investors yet, we believe it has not reached a proper market valuation. Do your due diligence on DCTH today.
Today we are highlighting: Delcath Systems, Inc. (DCTH), INSYS Therapeutics, Inc. (NASDAQ:INSY), Zynerba Pharmaceuticals, Inc. (ZYNE), Cara Therapeutics, Inc. (NASDAQ:CARA), and 22nd Century Group, Inc. (NYSE:XXII).
An interventional oncology company focused on treating liver cancers with major upside potential, Delcath Systems, Inc. (DCTH) (Market Cap: $3.025M, Share Price: $0.271), is an interventional oncology company focused on treating primary and metastatic liver cancers. The company as had quite a year. They announced an amendment to their ongoing Phase 3 clinical trial, raised $7 million, increased revenue 20% Y/Y, and were published in European Radiology among several other milestones.
DCTH made big news recently entering a licensing agreement for CHEMOSAT® commercialization in Europe with medac Gesellschaft für klinische Spezialpräparate mbH (medac). The agreement has a projected value of up to $45 million over the first seven-year term and includes an optional five-year extension. Medac is a privately held multi-national pharmaceutical company based in Hamburg area, Germany. Founded in 1970, Medac specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases. The company has offices globally, worldwide partner agreements in over 90 countries, and approximately 1,200 employees.
If the Company is able to complete enrollment in its Phase 3 ocular melanoma trial this year, there is potential for significant upside. Research DCTH now.
INSYS Therapeutics, Inc. (INSY) (Market Cap: $280.739M, Share Price: $3.78) announced positive results from its dose-finding pharmacokinetic (“PK”) study ?INS015-18-124?evaluating proprietary formulation of epinephrine nasal spray for treating anaphylaxis, an acute, life-threatening allergic reaction. Data from the study showed that the candidate has a similar PK profile with Mylan’s MYL EpiPen as well as Par Pharmaceuticals’ Adrenalin (epinephrine injection.
Zynerba Pharmaceuticals, Inc. (ZYNE) (Market Cap: $65.925M, Share Price: $3.74) released 12-month clinical data that describes the lifelong impact of ZYN002 on developmental and responsive symptoms of Fragile X syndrome. In a poster for the presentation in the 57th annual meeting, Professor Steven Siegel gives the presentation of the 12-month data of the second phase of the clinical trial of […] The post Zynerba Gives Clinical Update, Lifelong Impact of ZYN002 appeared first on Market Exclusive.
Cara Therapeutics, Inc. (CARA) (Market Cap: $593.674M, Share Price: $15.05) announced completion of enrollment in the KALM-1 Phase 3 trial of KORSUVA? (CR845/ difelikefalin), injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). More than 350 hemodialysis patients with CKD-aP have now been randomized across approximately 60 clinical sites in the United States.
22nd Century Group, Inc. (XXII) (Market Cap: $277.414M Share Price: $2.23) submitted a Modified Risk Tobacco Product (MRTP) application with the U.S. Food and Drug Administration (FDA) for the Company’s Very Low Nicotine Content (VLNC) cigarettes. 22nd Century’s proposed VLNTM cigarettes, the subject of the MRTP application, are made with the Company’s proprietary VLNTM tobacco and, as a result, contain very low levels of nicotine.
This article was written by Regal Consulting, LLC (“Regal Consulting”). Regal Consulting has agreed to a twelve-month term consulting agreement with DCTH dated 8/31/18. The agreement calls for $40,000 in cash, and 15,000 restricted 144 shares of DCTH per month. Issuer agreed to increase monthly cash payment in September to $120,000. All payments were made directly by Delcath Systems, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. DCTH was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
Microspeculators.com Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States
SOURCE: Regal Consulting, LLC